TIAA CREF Investment Management LLC grew its stake in shares of Solid Biosciences Inc (NASDAQ:SLDB) by 12.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,524 shares of the company’s stock after purchasing an additional 2,504 shares during the quarter. TIAA CREF Investment Management LLC owned approximately 0.06% of Solid Biosciences worth $1,063,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the business. Partner Fund Management L.P. raised its holdings in Solid Biosciences by 70.4% during the third quarter. Partner Fund Management L.P. now owns 799,777 shares of the company’s stock worth $37,733,000 after purchasing an additional 330,410 shares in the last quarter. BlackRock Inc. raised its holdings in Solid Biosciences by 30.6% during the third quarter. BlackRock Inc. now owns 778,249 shares of the company’s stock worth $36,718,000 after purchasing an additional 182,315 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Solid Biosciences in the 3rd quarter valued at $24,288,000. FMR LLC increased its holdings in shares of Solid Biosciences by 424.4% in the 3rd quarter. FMR LLC now owns 317,997 shares of the company’s stock valued at $15,003,000 after acquiring an additional 257,354 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Solid Biosciences by 21.2% in the 2nd quarter. Northern Trust Corp now owns 111,215 shares of the company’s stock valued at $3,963,000 after acquiring an additional 19,442 shares during the period. 63.59% of the stock is currently owned by institutional investors.

In related news, insider Joel Solomon Zev Schneider sold 21,990 shares of Solid Biosciences stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $30.84, for a total value of $678,171.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jorge Armando Quiroz sold 40,150 shares of Solid Biosciences stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $31.21, for a total transaction of $1,253,081.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 149,240 shares of company stock worth $4,614,793.

Shares of Solid Biosciences stock remained flat at $$7.42 during trading on Monday. 253,075 shares of the stock were exchanged, compared to its average volume of 1,180,182. Solid Biosciences Inc has a fifty-two week low of $5.97 and a fifty-two week high of $54.84. The firm has a market cap of $262.91 million and a PE ratio of -2.58.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. As a group, sell-side analysts forecast that Solid Biosciences Inc will post -2.21 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on SLDB shares. Citigroup started coverage on shares of Solid Biosciences in a report on Tuesday, November 6th. They issued a “sell” rating and a $25.00 target price on the stock. Leerink Swann cut shares of Solid Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday. Zacks Investment Research raised shares of Solid Biosciences from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Wednesday, October 17th. BTIG Research started coverage on shares of Solid Biosciences in a report on Monday, December 10th. They issued a “neutral” rating on the stock. Finally, Svb Leerink cut shares of Solid Biosciences from an “outperform” rating to a “market perform” rating in a report on Friday. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. Solid Biosciences currently has an average rating of “Hold” and an average target price of $35.00.

TRADEMARK VIOLATION NOTICE: “Solid Biosciences Inc (SLDB) Shares Bought by TIAA CREF Investment Management LLC” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/solid-biosciences-inc-sldb-shares-bought-by-tiaa-cref-investment-management-llc/2813231.html.

Solid Biosciences Company Profile

Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.

Recommended Story: Earnings Reports

Institutional Ownership by Quarter for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.